Evidence map›Paper›PMID 42084223›Full record

ArticleCancer research2026

CellFuse Enables Multimodal Integration of Single-Cell and Spatial Proteomics Data for Systems-Level Analysis in Cancer.

Abhishek Koladiya, Zinaida Good, Sricharan Reddy Varra, Pablo Domizi, Sean C Bendall, Kara L Davis

Abstract read
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Abhishek KoladiyaDivision of Hematology, Oncology, and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California.ORCID 0000-0002-7348-4048
Zinaida GoodDivision of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, California.ORCID 0000-0003-2343-5771
Sricharan Reddy VarraDivision of Hematology, Oncology, and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California.ORCID 0009-0000-5757-6818
Pablo DomiziDivision of Hematology, Oncology, and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California.ORCID 0000-0003-2903-0337
Sean C BendallDepartment of Pathology, Stanford University, Stanford, California.ORCID 0000-0003-1341-2453
Kara L DavisDivision of Hematology, Oncology, and Stem Cell Transplant and Regenerative Medicine, Department of Pediatrics, Stanford University, Stanford, California.ORCID 0000-0002-7182-2592

Funding

Predicting Relapse at the Time of Diagnosis in Acute Lymphoblastic LeukemiaR01CA251858 · NCI · STANFORD UNIVERSITY · PI DAVIS, KARA LYNN · 2021 to 2025
$3.1M
Mark Foundation For Cancer Research (MFCR) ASPIRE awardNational Cancer Institute (NCI) R01-CA251858NCI NIH HHS R01 CA251858Stanford Maternal and Child Health Research Institute (MCHRI)
6 · The paper itself

Abstract

Analysis of tumors using single-cell and spatial modalities is critical to advance our understanding of cancer. The growth of technologies that enable these studies provides an increasing number of single cell datasets. Integrating such data across studies will increase the impact of individual studies and speed cancer research. Most existing integration approaches are tailored to transcriptomic data and assume large sets of shared features, an assumption that fails for lower dimensional proteomic measurements. Here, we developed CellFuse, a deep learning-based integration framework that unifies antibody-based proteomic datasets, including high-dimensional cytometry, cellular indexing of transcriptomes and epitopes by sequencing, and spatial proteomics data. Leveraging supervised contrastive learning, CellFuse learned a shared embedding space that enabled accurate cross-modality cell-type prediction and robust label transfer across tumor samples and experimental conditions. Applied to datasets spanning peripheral blood, bone marrow, and lymphoma, CellFuse consistently outperformed existing approaches in recovering clinically relevant populations, including rare malignant and immune subsets. In solid tumors, it reconstructed spatially resolved microenvironments, capturing interactions between malignant, stromal, and immune cells that correlated with treatment response. By enabling scalable, modality-agnostic integration, CellFuse provides a powerful tool to uncover prognostic cell states and delineate the architecture of the tumor-immune ecosystem with translational relevance, driving cancer discoveries. SIGNIFICANCE: CellFuse is a supervised contrastive learning framework enabling accurate, scalable integration of single-cell proteomic and transcriptomic data, overcoming sparse marker overlap and differing distributions to improve analysis of single-cell data in cancer.

Indexed as

NeoplasmsProteomicsSingle-Cell AnalysisAnimalsDeep LearningHumansTumor Microenvironment

Identifiers

PMID42084223
PMCPMC13370112

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.